Teva price target raised to $21 from $20 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Teva to $21 from $20 and keeps an Overweight rating on the shares after meeting with management. The analyst is “incrementally positive” on Teva’s research and development progress, with growth led by biosimilars.